Correspondence 0001213900-24-086845 from Pasithea Therapeutics Corp. (KTTA)
Pasithea Therapeutics Corp.
Date: Oct. 10, 2024 · CIK: 0001841330 · Accession: 0001213900-24-086845
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-282532
Letter
VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance File No. 333-282532 Acceleration Request Requested Date: October 11, 2024 Requested Time: 5:00 p.m., Eastern Time
Re: Pasithea Therapeutics Corp.
Dear Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Pasithea Therapeutics Corp. (the “Company”) hereby requests that the above-referenced Registration Statement (the “Registration Statement”) be declared effective by the Securities and Exchange Commission (the “Commission”) at the “Requested Date” and “Requested Time” set forth above or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Commission.
Please call Tracy Buffer of Lowenstein Sandler LLP at (973) 597-2434 to confirm the effectiveness of the Registration Statement or with any questions.
Sincerely,
PASITHEA THERAPEUTICS CORP.
Show Raw Text
CORRESP
1
filename1.htm
October 10, 2024
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
Mail Stop 4720
100 F Street, N.E.
Washington, D.C. 20549
Re:
Pasithea Therapeutics Corp.
Registration Statement on Form S-3
File No. 333-282532
Acceleration Request
Requested Date:
October 11, 2024
Requested Time:
5:00 p.m., Eastern Time
Dear Ladies and Gentlemen:
Pursuant to Rule 461
under the Securities Act of 1933, as amended, Pasithea Therapeutics Corp. (the “Company”) hereby requests that the above-referenced
Registration Statement (the “Registration Statement”) be declared effective by the Securities and Exchange Commission (the
“Commission”) at the “Requested Date” and “Requested Time” set forth above or at such later time as
the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Commission.
Please call Tracy Buffer of Lowenstein Sandler LLP
at (973) 597-2434 to confirm the effectiveness of the Registration Statement or with any questions.
Sincerely,
PASITHEA THERAPEUTICS CORP.
By:
/s/ Tiago Reis Marques
Name:
Tiago Reis Marques
Title:
Chief Executive Officer